Acadia Pharmaceuticals Inc Stock Price, News & Analysis

Acadia Pharmaceuticals (NASDAQ: ACAD) reported Q3 2025 total revenues of $278.6M, up 11% year-over-year, driven by NUPLAZID sales of $177.5M (+12% YoY) and DAYBUE sales of $101.1M (+11% YoY). Net income was $71.8M ($0.42 diluted), versus $32.8M a year ago, reflecting higher pre-tax income and a one-time tax benefit from the One Big Beautiful Bill Act. Cash and investments totaled $847.0M at September 30, 2025. R&D expense rose to $87.8M for the quarter. Full-year 2025 guidance was updated: total revenues $1.070–$1.095B, NUPLAZID $685–$695M, DAYBUE $385–$400M, with R&D and SG&A ranges provided.

Acadia Pharmaceuticals (Nasdaq: ACAD) will participate at two investor conferences in November 2025.

UBS Global Healthcare Conference fireside chat: Monday, November 10, 2025 at 2:00 p.m. ET in Palm Beach Gardens, FL. Jefferies Global Healthcare Conference presentation: Tuesday, November 18, 2025 at 8:30 a.m. GMT in London.

Live webcasts will be accessible on Acadia’s investor website and archived recordings will be available for about one month after each presentation. The company described its commercial portfolio and mid‑ to late‑stage pipeline in neurological and rare disease programs, including treatments for Parkinson’s disease psychosis and Rett syndrome.

Acadia Pharmaceuticals (Nasdaq: ACAD) will report third quarter 2025 financial results on Wednesday, November 5, 2025 after U.S. market close. Management will host a conference call and webcast on November 5, 2025 at 4:30 p.m. Eastern Time.

The webcast will be available on Acadia's investor website and archived there until February 5, 2026. Registration provides dial-in number and unique PIN for the call. Acadia's commercial portfolio includes FDA-approved treatments for Parkinson’s disease psychosis and Rett syndrome, and the pipeline includes mid-to-late-stage programs in Alzheimer’s disease psychosis and Lewy body dementia psychosis.

Acadia Pharmaceuticals (NASDAQ: ACAD) announced three presentations at the 2025 International Congress of Parkinson's Disease and Movement Disorders® in Honolulu. The presentations include: a late-breaker oral platform presentation on ACP-711 for essential tremor, showing preclinical efficacy and safety data; a poster on the Phase 2 study design of ACP-204 for Lewy body dementia psychosis; and findings from a post-hoc analysis of NUPLAZID® (pimavanserin) in Parkinson's disease psychosis.

NUPLAZID, approved by the FDA in April 2016, is indicated for treating hallucinations and delusions associated with Parkinson's disease psychosis. The drug selectively targets 5-HT2A receptors and carries important safety considerations, including warnings about increased mortality in elderly patients with dementia-related psychosis and QT interval prolongation.

Acadia Pharmaceuticals (Nasdaq: ACAD) announced disappointing results from its Phase 3 COMPASS PWS trial evaluating intranasal carbetocin (ACP-101) for hyperphagia in Prader-Willi syndrome. The trial failed to meet its primary endpoint, showing no statistically significant improvement over placebo on the Hyperphagia Questionnaire for Clinical Trials (HQ-CT) at Week 12.

The study, which enrolled 175 patients aged 5-30 years, also showed no separation from placebo on secondary endpoints, though the safety profile remained consistent with previous trials. Despite this setback, Acadia maintains a positive outlook, projecting over $1 billion in net sales for 2025 from two approved products and anticipates seven Phase 2 or 3 study starts through 2026 and four data readouts by 2027.

Acadia Pharmaceuticals (NASDAQ:ACAD) published interim results from the LOTUS study evaluating DAYBUE® (trofinetide) in Rett syndrome patients. The study, involving 227 patients aged 1-60 years, demonstrated significant effectiveness in real-world settings over 12 months.

Key findings showed 71-90% of patients reported behavioral improvements, with notable progress in nonverbal communication (48-71%), alertness (44-70%), and social interaction (33-58%). The study also provided insights into managing gastrointestinal symptoms, with diarrhea incidence varying between 23-50% in weeks 1-12 and 26-38% in months 4-12.

The median dose reached at least 80% of the labeled dose by Week 10, starting from 36% at Week 1. The Quality-of-Life assessment showed a median improvement of 4.6 points over 12 months.

Acadia Pharmaceuticals (NASDAQ: ACAD) announced inducement grants to eighteen new employees under its 2024 Inducement Plan. The grants include non-qualified stock options for 161,676 shares at $25.50 per share and 49,363 restricted stock units (RSUs).

The stock options will vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs will vest over four years, with 50% vesting after two years and the remaining 50% in two equal annual installments. All grants are subject to continued employment with Acadia.

Acadia is known for developing the first FDA-approved treatment for Parkinson's disease psychosis and Rett syndrome in the US and Canada. The company continues to focus on neuroscience and neuro-rare diseases, including programs for Prader-Willi syndrome and Alzheimer's disease psychosis.

Acadia Pharmaceuticals (NASDAQ: ACAD) announced its participation in three upcoming investor conferences in September 2025. The company will present at the Morgan Stanley Global Healthcare Conference (Sept. 8), H.C. Wainwright Global Investment Conference (Sept. 9), and TD Cowen's Novel Mechanisms in Neuropsychiatry & Epilepsy Summit (Sept. 18).

Acadia specializes in neurological and rare diseases, having developed FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. Their current clinical pipeline includes programs for Prader-Willi syndrome and Alzheimer's disease psychosis. Live webcasts of the presentations will be available on acadia.com with recordings accessible for approximately one month.

Acadia Pharmaceuticals (Nasdaq: ACAD) has appointed Konstantina "Tina" Katcheves as Senior Vice President, Chief Business and Strategy Officer. Reporting to CEO Catherine Owen Adams, Katcheves will lead the company's business development and corporate strategy initiatives.

Katcheves brings over 20 years of biopharmaceutical industry experience, most recently serving as Senior Vice President, Global Business Development at Teva Pharmaceuticals. At Bristol Myers Squibb, she led the $14 billion acquisition of Karuna Therapeutics and drove more than $18 billion in announced transactions. She previously held senior roles at Agilent Technologies and Lonza Group.